Literature DB >> 30506169

Study of Percutaneous Stent Placement with Iodine-125 Seed Strand for Malignant Biliary Obstruction.

Wei-Zhong Zhou1, Yong-Meng Fu1, Zheng-Qiang Yang2, Hai-Bin Shi1, Sheng Liu1, Jin-Guo Xia1, Chun-Gao Zhou1.   

Abstract

PURPOSE: To evaluate the effectiveness and safety of simultaneous placement of a self-expandable metallic stents (SEMS) and iodine-125 seed strand in the management of malignant obstructive jaundice (MOJ).
MATERIALS AND METHODS: This study included 132 patients with MOJ treated from November 2015 to October 2017. Forty-five patients underwent insertion of SEMS with iodine-125 seed strands (Seeds group); the remaining 87 patients underwent SEMS placement alone (Control group). Technical success was defined as accurate, successful deployment of SEMS with or without iodine-125 seed strand; clinical success was defined as 20% reduction in serum bilirubin within 1 week after the procedure, compared with baseline. Complications, duration of primary stent patency, and overall survival were evaluated.
RESULTS: Technical success was achieved in all patients in both groups. In the Seeds group, an average of 14 seeds (range 8-22) were implanted in the bile duct as a strand. Clinical success rates were similar between the groups (Seeds group, 93.3%; Control group, 95.4%). Major complications occurred in only one patient, in the Control group. The median period of primary stent patency was significantly longer in the Seeds group (194 days) than in the Control group (86 days; P = 0.049). The median overall survival was also significantly longer in the Seeds group (194 days) than in the Control group (96 days; P = 0.031).
CONCLUSION: SEMS combined with iodine-125 seed strands is effective and safe in the management of MOJ and can improve stent patency and patient survival.

Entities:  

Keywords:  Iodine-125 seed; Malignant obstructive jaundice; Self-expandable metallic stent; Stent patency; Survival

Mesh:

Substances:

Year:  2018        PMID: 30506169     DOI: 10.1007/s00270-018-2117-7

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

1.  Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice.

Authors:  Hui-Wen Wang; Xiao-Jing Li; Shi-Jie Li; Jun-Rong Lu; Dong-Feng He
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

2.  Self-expandable metallic stent with 125I seed strand in malignant biliary obstruction: a self-made delivery system and novel implantation method.

Authors:  Rui An; Hu Zhang; Jing Yu; Yunbao Cao; Jialiang Ren; Wangang Guo; Zhonghua Luo
Journal:  Ann Transl Med       Date:  2021-12

3.  Brachytherapy Drainage Catheter and Chemotherapy for Unresectable Pancreatic Carcinoma Combined with Obstructive Jaundice.

Authors:  Dechao Jiao; Kaihao Xu; Gauri Mukhiya; Yiming Liu; Kunpeng Wu; Zongming Li; Jianzhuang Ren; Xinwei Han
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

4.  Biliary self-expandable metallic stent combined with Iodine-125 seeds strand in the treatment of hilar malignant biliary obstruction.

Authors:  Chuanguo Zhou; Hui Li; Qiang Huang; Jianfeng Wang; Kun Gao
Journal:  J Int Med Res       Date:  2019-12-29       Impact factor: 1.671

5.  Percutaneous biliary stent combined with brachytherapy using 125I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis.

Authors:  Wei-Yue Chen; Chun-Li Kong; Miao-Miao Meng; Wei-Qian Chen; Li-Yun Zheng; Jian-Ting Mao; Shi-Ji Fang; Li Chen; Gao-Feng Shu; Yang Yang; Qiao-You Weng; Min-Jiang Chen; Min Xu; Jian-Song Ji
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

6.  A Comparative Study of Self-Expandable Metallic Stent Combined with Double 125I Seeds Strands or Single 125I Seeds Strand in the Treatment of Advanced Perihilar Cholangiocarcinoma with Malignant Obstructive Jaundice.

Authors:  Zhaonan Li; Dechao Jiao; Xinwei Han; Zaoqu Liu
Journal:  Onco Targets Ther       Date:  2021-07-06       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.